Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|August 12, 2002

Colorectal Cancer Drug Approved on 'Fast Track'

12 AUGUST ? After its fastest review yet for a cancer drug, FDA has approved the colorectal cancer drug Eloxatin (oxaliplatin).

Colorectal Cancer Drug Approved on 'Fast Track'—After its fastest review yet for a cancer drug, FDA has approved thecolorectal cancer drug Eloxatin (oxaliplatin). Used in combination withother cancer drugs, the drug was shown to shrink tumors in some patients anddelay resumed tumor growth.http://www.fda.gov/bbs/topics/NEWS/2002/NEW00825.html


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.